SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
34,200
+350 (1.03%)
Aug 3, 2026, 3:30 PM KST

SK bioscience Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-83,286-57,424-53,88122,318122,452355,139
Depreciation & Amortization
95,27591,01649,22534,76527,23618,775
Loss (Gain) From Sale of Assets
-30,983-30,979-14,25968.06434.6-23.62
Asset Writedown & Restructuring Costs
--1.411,154--
Loss (Gain) From Sale of Investments
-4,010-10,444-24,162-13,777-36,875-892.14
Provision & Write-off of Bad Debts
-239.42-25.41-81.7-29.33-21.08-9.4
Other Operating Activities
1,851-14,385-124,9253,240-29,807119,603
Change in Accounts Receivable
-24,636-19,883-2,47226,674-4,770-7,595
Change in Inventory
22,81231,52379,41052,888-96,230-70,337
Change in Accounts Payable
1,80915,840-1,243-7,683-52,75946,536
Change in Other Net Operating Assets
18,50397,270-35,632-90,271-54,62075,397
Operating Cash Flow
-2,770102,507-128,02029,346-124,958536,594
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-177,077-183,091-164,413-43,461-72,993-42,907
Sale of Property, Plant & Equipment
51,42351,35516,5290.5434.5747.08
Cash Acquisitions
-3,615-3,615-216,758---
Sale (Purchase) of Intangibles
-101,065-77,257-7,811-6,834-3,497-1,562
Investment in Securities
-91,941-150,768423,3297,377352,052-1,384,617
Other Investing Activities
900.231,6162,688-2,361-2,951-235.56
Investing Cash Flow
-324,266-361,76053,564-45,279272,647-1,421,940

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---1,00048,74211,324
Long-Term Debt Issued
-50,049192,057---
Total Debt Issued
110,04950,049192,0571,00048,74211,324
Short-Term Debt Repaid
----45,425-16,196-50
Long-Term Debt Repaid
--9,244-10,791-51,039-55,031-35,521
Total Debt Repaid
-9,545-9,244-10,791-96,464-71,227-35,571
Net Debt Issued (Repaid)
100,50440,806181,266-95,464-22,485-24,247
Issuance of Common Stock
993.73794.775,680397.62,618983,256
Other Financing Activities
-0-0-4,4675,484--628.09
Financing Cash Flow
101,49841,600252,479-89,583-19,867958,380

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
6,51010,5047,6537,253-561.8722.25
Net Cash Flow
-219,027-207,149185,676-98,262127,25973,056

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-179,846-80,584-292,433-14,114-197,951493,686
Free Cash Flow Growth
------
Free Cash Flow Margin
-27.03%-12.37%-109.30%-3.82%-43.34%53.14%
Free Cash Flow Per Share
-2294.30-1028.30-3787.93-183.27-2570.086686.61
Levered Free Cash Flow
-314,999-154,803-345,40813,402-203,405-
Unlevered Free Cash Flow
-308,305-148,929-343,10514,276-201,867-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
12,22710,6763,5671,3972,6813,407
Cash Income Tax Paid
-6,7764,65825,639104,2108,987
Change in Working Capital
18,488124,75140,063-18,392-208,37944,001